Success Metrics

Clinical Success Rate
81.2%

Based on 56 completed trials

Completion Rate
81%(56/69)
Active Trials
8(9%)
Results Posted
73%(41 trials)
Terminated
13(15%)

Phase Distribution

Ph phase_1
6
7%
Ph phase_2
22
26%
Ph phase_4
12
14%
Ph early_phase_1
1
1%
Ph not_applicable
14
16%
Ph phase_3
30
35%

Phase Distribution

7

Early Stage

22

Mid Stage

42

Late Stage

Phase Distribution85 total trials
Early Phase 1First-in-human
1(1.2%)
Phase 1Safety & dosage
6(7.1%)
Phase 2Efficacy & side effects
22(25.9%)
Phase 3Large-scale testing
30(35.3%)
Phase 4Post-market surveillance
12(14.1%)
N/ANon-phased studies
14(16.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

56 of 72 finished

Non-Completion Rate

22.2%

16 ended early

Currently Active

8

trials recruiting

Total Trials

85

all time

Status Distribution
Active(9)
Completed(56)
Terminated(16)
Other(4)

Detailed Status

Completed56
Terminated13
Recruiting7
unknown4
Withdrawn3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
85
Active
8
Success Rate
81.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.2%)
Phase 16 (7.1%)
Phase 222 (25.9%)
Phase 330 (35.3%)
Phase 412 (14.1%)
N/A14 (16.5%)

Trials by Status

recruiting78%
not_yet_recruiting11%
terminated1315%
unknown45%
withdrawn34%
completed5666%
active_not_recruiting11%

Recent Activity

Clinical Trials (85)

Showing 20 of 85 trialsScroll for more
NCT06999057Early Phase 1

Quadriceps Motor Unit Adaptation to Simulated Knee Injury

Recruiting
NCT06951191Phase 4

Intrauterine Device Insertion Pain Management

Terminated
NCT07282457Phase 1

Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)

Not Yet Recruiting
NCT03845049Phase 3

Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

Terminated
NCT05587205Phase 1

Safety and Tolerability of EO2002

Recruiting
NCT07174167Not Applicable

Genicular Nerve Block in Chronic Knee Osteoarthritis

Completed
NCT05486468Phase 3

The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment

Recruiting
NCT03607838Phase 3

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

Completed
NCT06456255Phase 2

Bupivacaine and Epinephrine Injection Study

Recruiting
NCT06270836Phase 3

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Active Not Recruiting
NCT06615505Phase 2

ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs

Recruiting
NCT04744662Phase 1

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Completed
NCT03868995Not Applicable

The Efficacy of Hypertonic Dextrose Injection to Anterior Talofibular Ligament Sprain

Completed
NCT06541574Phase 2

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

Recruiting
NCT05066230Phase 3

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

Terminated
NCT04945772Phase 2

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Completed
NCT03867604Not Applicable

Ultrasound-guided Fascial Release Injection for Myofascial Pain Syndrome in the Upper Trapezius Muscle

Completed
NCT01668953Not Applicable

Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)

Terminated
NCT00309192Phase 3

Efficacy and Safety Study of Intravitreal Triamcinolone to Treat Diffuse Diabetic Macular Edema

Completed
NCT03802630Phase 3

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Terminated

Drug Details

Intervention Type
OTHER
Total Trials
85